P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL

ABSTRACT:

SUBMITTER: Facon T 

PROVIDER: S-EPMC10171558 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature